GSA Capital Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

GSA Capital Partners’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,104	Closed	-$828K	–	1787
2025 Q4	$828K	Buy	33,104 +14,343	+76%	+$363K	0.07%	471
2025 Q3	$455K	Buy	+18,761	New	+$333K	0.04%	911
2025 Q1	–	Sell	-71,947	Closed	-$1.21M	–	1713
2024 Q4	$1.21M	Sell	71,947 -21,711	-23%	-$360K	0.09%	286
2024 Q3	$1.5M	Buy	93,658 +37,275	+66%	+$457K	0.11%	214
2024 Q2	$509K	Buy	56,383 +42,796	+315%	+$406K	0.04%	952
2024 Q1	$154K	Buy	+13,587	New	+$129K	0.01%	1442

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

GSA Capital Partners's CNTA Position: Q1 2026 in Review

GSA Capital Partners sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 33,104 shares — an estimated $828K sold.

GSA Capital Partners first reported a position in CNTA in Q1 2024 and held it in 6 quarters. The position peaked at $1.5M in Q3 2024. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

GSA Capital Partners reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 33,104 Centessa Pharmaceuticals shares in Q1 2026, an estimated $828K.
GSA Capital Partners first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 6 quarters.
GSA Capital Partners's Centessa Pharmaceuticals position peaked at $1.5M in Q3 2024.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.